Naciri Bennani H, Bonzi JY, Noble J, et al. - In this study done on 7 patients (mean age = 45 ± 10 years) with recurrent focal and segmental glomerulosclerosis (FSGS) on kidney allograft (proteinuria ≥ 3 g/g of urinary creatinine or ≥ 3 g/day) who were treated with immunoadsorption [IA], researchers investigated whether IA is efficacious as an option to treat recurrent FSGS. The participants received either rituximab alone (n = 3), rituximab plus either PP (plasma exchange plasmapheresis) or IA (n = 3), or no treatment (n = 1) as prophylaxis to prevent FSGS recurrence. They observed partial (n = 6) or complete (n = 1) remission in all patients at 12 months after commencing IA, and allograft survival was 100%. An IA session brought about a mean reduction of 45 ± 15% in proteinuria. The last follow-up revealed remission in 2 patients without IA, IA dependent partial remission in 3 patients, and loss of allograft due to FSGS recurrence in 2 patients. Cytomegalovirus reactivation (n = 13) was reported as the most common adverse event, which subsided following valganciclovir therapy. Overall, experts concluded that IA plus rituximab can control FSGS recurrence during the long term. However, some patients continued to be dependent on IA.